핵산 치료제 위탁생산 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 서비스별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)
Nucleic Acid Therapeutics Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End Use, By Application, By Region, And Segment Forecasts, 2025 - 2033
상품코드
:
1888752
리서치사
:
Grand View Research
발행일
:
2025년 11월
페이지 정보
:
영문 120 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
핵산 치료제 위탁생산 시장 요약
세계의 핵산 치료제 위탁생산 시장 규모는 2024년에 98억 5,000만 달러로 추정되며, 2033년까지 338억 4,000만 달러에 달할 것으로 예측됩니다.
2025년부터 2033년까지 CAGR 15.14%로 성장할 것으로 예상됩니다. 본 시장은 바이오의약품 아웃소싱 증가 추세, mRNA 치료 및 유전자 치료 수요 확대, 제조 기술 발전에 힘입어 지속적으로 성장하고 있습니다.
규제적 지원 강화와 정부의 우대 정책도 시장 성장을 촉진하는 요인 중 하나입니다. 세계 시장에서는 바이오제약기업들이 위탁생산업체에 업무를 위탁하는 추세가 증가하면서 시장 성장을 견인할 것으로 예상됩니다. 이 위탁 활동을 통해 운영 비용 절감, 시장 출시 시간 단축, 핵산 생산에 대한 전문 지식 활용이 가능합니다. 2025년 7월에 발표된 기사에 따르면, 세포-유전자 치료(CGT) 기업의 82.6%가 생물학적 제제 제조의 최소 일부를 외부에 위탁하고 있으며, 외부 위탁 제조 서비스에 대한 의존도가 사상 최고 수준에 이르렀다고 합니다.
또한, mRNA, 플라스미드 DNA, 올리고뉴클레오티드 치료제는 고도의 복잡성을 가지고 있고, GMP 인증 시설, 숙련된 인력, 첨단 기술이 필요하기 때문에 아웃소싱 활동이 촉진되고 있습니다. 이에 따라 수탁 제조업체는 공정 개발, 분석 테스트, 상업적 규모의 제조를 포함한 통합 서비스에 대한 수요가 증가하고 있습니다. 또한, 아웃소싱을 통해 제약회사는 연구개발에 집중할 수 있고, 규제 준수 및 품질 기준 달성을 보장할 수 있습니다.
목차 제1장 조사 방법과 범위
제2장 주요 요약
제3장 핵산 치료제 위탁생산 시장 변수, 동향 및 범위
시장 계통 전망
시장 역학
기술 동향
가격 모델 분석
관세 영향 분석
밸류체인 분석
시장 분석 툴
Porter's Five Forces 분석
SWOT 분석에 의한 PESTEL 분석
제4장 핵산 치료제 위탁생산 시장 : 유형별 추정·동향 분석
핵산 치료제 위탁생산 시장 : 유형별 : 변동 분석
핵산 치료제 위탁생산 시장 추정·예측 : 유형별, 2021-2033년
유전자 치료
플라스미드 DNA(pDNA)
바이러스 벡터
비바이러스성 유전자 도입 시스템
기타
RNA 기반 치료법
메신저 RNA(mRNA)
소간섭 RNA(siRNA)
안티센스 올리고뉴클레오티드(ASO)
기타
제5장 핵산 치료제 위탁생산 시장 : 서비스별 추정·동향 분석
핵산 치료제 위탁생산 시장 : 서비스별 변동 분석
핵산 치료제 위탁생산 시장 추정 및 예측 : 서비스별, 2021-2033년
프로세스 개발 및 최적화
GMP 제조
분석·품질 관리 서비스
충전·포장 위탁생산
규제 지원
기타
제6장 핵산 치료제 위탁생산 시장 : 용도별 추정·동향 분석
핵산 치료제 위탁생산 시장 : 용도별 변동 분석
핵산 치료제 위탁생산 시장 추정 및 예측 : 용도별, 2021-2033년
종양학
희귀질환
유전성 질환
감염증
기타
제7장 핵산 치료제 위탁생산 시장 : 최종 용도별 추정·동향 분석
핵산 치료제 위탁생산 시장 : 최종 용도별 변동 분석
핵산 치료제 위탁생산 시장 추정·예측 : 최종 용도별, 2021-2033년
주요 바이오의약품 기업
중규모 바이오의약품 기업
중소 바이오의약품 기업
기타
제8장 핵산 치료제 위탁생산 시장 : 지역별 추정·동향 분석
지역별 시장 대시보드
지역별 시장 점유율 분석(2024년 및 2033년)
북미
유럽
영국
독일
프랑스
이탈리아
스페인
덴마크
스웨덴
노르웨이
아시아태평양
라틴아메리카
중동 및 아프리카
남아프리카공화국
아랍에미리트
사우디아라비아
쿠웨이트
카타르
오만
제9장 경쟁 구도
주요 참여자 분류
2024년 시장 점유율/평가 분석(히트맵 분석)
기업 개요
Lonza Group
Thermo Fisher Scientific
Catalent Inc.
WuXi AppTec
AGC Biologics
Agilent Technologies
Ajinomoto Bio-Pharma Services
BioSpring GmbH
Bachem Holding AG
CordenPharma International GmbH
Danaher Corporation
Eurofins Scientific
Avecia(Nitto Denko/Avecia)
BioCina Pty Ltd.
Kaneka Corporation
KSM
영문 목차
Nucleic Acid Therapeutics Contract Manufacturing Market Summary
The global nucleic acid therapeutics contract manufacturing market size was estimated at USD 9.85 billion in 2024 and is projected to reach USD 33.84 billion by 2033, growing at a CAGR of 15.14% from 2025 to 2033. The market is witnessing growth driven by growing biopharmaceutical outsourcing trends, rising demand for mRNA and gene therapies, and technological advancements in manufacturing.
Increasing regulatory support and government incentives are among the other factors driving market growth. In the global market, shifting trends towards outsourcing activities by biopharmaceutical companies to contract manufacturers are expected to drive market growth. This outsourcing activity reduces operational costs, accelerates time-to-market, and utilizes specialized expertise in nucleic acid production. According to an article published in July 2025, 82.6% of cell and gene therapy (CGT) companies outsource at least part of their biologics manufacturing, marking record-high levels of reliance on external contract manufacturing services.
In addition, outsourcing activities is also driven by the high complexity of mRNA, plasmid DNA, and oligonucleotide therapeutics, which require GMP-certified facilities, skilled personnel, and advanced technologies. Thus, contract manufacturers are witnessing an increasing requirement for integrated services, including process development, analytical testing, and commercial-scale manufacturing. In addition, outsourcing enables pharmaceutical firms to concentrate on research and development, ensuring that regulatory compliance and quality standards are met.
Global Nucleic Acid Therapeutics Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nucleic acid therapeutics contract manufacturing market report based on type, service, application, end use, and region:
Type Outlook (Revenue, USD Million, 2021 - 2033)
Gene Therapy
Plasmid DNA (pDNA)
Viral Vectors
Non-viral Gene Delivery Systems
Others
RNA-based Therapies
Messenger RNA (mRNA)
Small Interfering RNA (siRNA)
Antisense Oligonucleotides (ASO)
Other
Service Outlook (Revenue, USD Million, 2021 - 2033)
Process Development and Optimization
GMP Manufacturing
Analytical and Quality Control Service
Fill-Finish Contract Manufacturing
Regulatory Support
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Rare Diseases
Genetic Disorders
Infectious Diseases
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Large Biopharmaceutical Companies
Medium Biopharmaceutical Companies
Small Biopharmaceutical Companies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Middle East & Africa
South Africa
UAE
Saudi Arabia
Kuwait
Qatar
Oman
Table of Contents Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Service
1.2.3. Application
1.2.4. End Use
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR's Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Top-Down Analysis
1.7.3. Botton-Up Approach
1.7.4. Multivariate Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Nucleic Acid Therapeutics Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Demand for Cell and Gene Therapies
3.2.1.2. Increased Outsourcing by Biopharma Companies
3.2.1.3. Technological Advancements in Manufacturing Platforms
3.2.2. Market Restraint Analysis
3.2.2.1. High Production Complexity and Cost
3.2.2.2. Limited Skilled Workforce and Technical Expertise
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Tariff Impact Analysis
3.6. Value Chain Analysis
3.6.1. Supply Trends
3.6.2. Demand Trends
3.7. Market Analysis Tools
3.7.1. Porter's Five Force Analysis
3.7.2. PESTEL by SWOT Analysis
Chapter 4. Nucleic Acid Therapeutics Contract Manufacturing Market: Type Estimates & Trend Analysis
4.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Type: Segment Dashboard
4.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Type: Movement Analysis
4.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
4.4. Gene Therapy
4.4.1. Gene Therapy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.2. Plasmid DNA (pDNA)
4.4.2.1. Plasmid DNA (pDNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.3. Viral Vectors
4.4.3.1. Viral Vectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.4. Non-viral Gene Delivery Systems
4.4.4.1. Non-viral Gene Delivery Systems Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.5. Others
4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. RNA-based Therapies
4.5.1. RNA-based Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Messenger RNA (mRNA)
4.5.2.1. Messenger RNA (mRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Small Interfering RNA (siRNA)
4.5.3.1. Small Interfering RNA (siRNA) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.4. Antisense Oligonucleotides (ASO)
4.5.4.1. Antisense Oligonucleotides (ASO) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.5. Others
4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Nucleic Acid Therapeutics Contract Manufacturing Market: Service Estimates & Trend Analysis
5.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Service: Segment Dashboard
5.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Service: Movement Analysis
5.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
5.4. Process Development and Optimization
5.4.1. Process Development and Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. GMP Manufacturing
5.5.1. GMP Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Analytical and Quality Control Service
5.6.1. Analytical and Quality Control Service Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Fill-Finish Contract Manufacturing
5.7.1. Fill-Finish Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Regulatory Support
5.8.1. Regulatory Support Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Others
5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Nucleic Acid Therapeutics Contract Manufacturing Market: Application Estimates & Trend Analysis
6.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By Application: Segment Dashboard
6.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By Application: Movement Analysis
6.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By Application, 2021 - 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Rare Diseases
6.5.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Genetic Disorders
6.6.1. Genetic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Infectious Diseases
6.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Nucleic Acid Therapeutics Contract Manufacturing Market: End Use Estimates & Trend Analysis
7.1. Nucleic Acid Therapeutics Contract Manufacturing Market, By End Use: Segment Dashboard
7.2. Nucleic Acid Therapeutics Contract Manufacturing Market, By End Use: Movement Analysis
7.3. Nucleic Acid Therapeutics Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
7.4. Large Biopharmaceutical Companies
7.4.1. Large Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Medium Biopharmaceutical Companies
7.5.1. Medium Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Small Biopharmaceutical Companies
7.6.1. Small Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Nucleic Acid Therapeutics Contract Manufacturing Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Regional Market Share Analysis, 2024 & 2033
8.3. North America
8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. U.S
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. Canada
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.4. Mexico
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4. Europe
8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.2. UK
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Germany
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. France
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.5. Italy
8.4.5.1. Key Country Dynamics
8.4.5.2. Competitive Scenario
8.4.5.3. Regulatory Framework
8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.6. Spain
8.4.6.1. Key Country Dynamics
8.4.6.2. Competitive Scenario
8.4.6.3. Regulatory Framework
8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.7. Denmark
8.4.7.1. Key Country Dynamics
8.4.7.2. Competitive Scenario
8.4.7.3. Regulatory Framework
8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.8. Sweden
8.4.8.1. Key Country Dynamics
8.4.8.2. Competitive Scenario
8.4.8.3. Regulatory Framework
8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.9. Norway
8.4.9.1. Key Country Dynamics
8.4.9.2. Competitive Scenario
8.4.9.3. Regulatory Framework
8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Asia Pacific
8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. Japan
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. China
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. India
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Australia
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Thailand
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. South Korea
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Latin America
8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Brazil
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. Argentina
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. MEA
8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. South Africa
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. UAE
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.4. Saudi Arabia
8.7.4.1. Key Country Dynamics
8.7.4.2. Competitive Scenario
8.7.4.3. Regulatory Framework
8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.5. Kuwait
8.7.5.1. Key Country Dynamics
8.7.5.2. Competitive Scenario
8.7.5.3. Regulatory Framework
8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.6. Qatar
8.7.6.1. Key Country Dynamics
8.7.6.2. Competitive Scenario
8.7.6.3. Regulatory Framework
8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.7. Oman
8.7.7.1. Key Country Dynamics
8.7.7.2. Competitive Scenario
8.7.7.3. Regulatory Framework
8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Key Participant Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
9.3. Company Profiles
9.3.1. Lonza Group
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Thermo Fisher Scientific
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Catalent Inc.
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. WuXi AppTec
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. AGC Biologics
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Agilent Technologies
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Ajinomoto Bio-Pharma Services
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. BioSpring GmbH
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Bachem Holding AG
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. CordenPharma International GmbH
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Danaher Corporation
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Service Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Eurofins Scientific
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Service Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. Avecia (Nitto Denko / Avecia)
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Service Benchmarking
9.3.13.4. Strategic Initiatives
9.3.14. BioCina Pty Ltd.
9.3.14.1. Company Overview
9.3.14.2. Financial Performance
9.3.14.3. Service Benchmarking
9.3.14.4. Strategic Initiatives
9.3.15. Kaneka Corporation
9.3.15.1. Company Overview
9.3.15.2. Financial Performance
9.3.15.3. Service Benchmarking
9.3.15.4. Strategic Initiatives
관련자료
